Aggressive lipid-lowering therapy after percutaneous coronary intervention - for whom and how?: Aggressive...

Area of Science:

• Cardiology
• Preventive Medicine
• Pharmacology

Background:

• Percutaneous coronary intervention (PCI) effectively treats obstructive coronary artery disease.
• PCI alone is insufficient for optimal long-term outcomes; risk factor control is crucial.
• Atherosclerosis and dyslipidemia necessitate robust secondary prevention strategies to mitigate cardiovascular events and procedural failure.

Purpose of the Study:

• To review current lipid-lowering therapies for secondary prevention in patients post-PCI.
• To summarize guideline recommendations for managing dyslipidemia.
• To highlight the evidence and rationale for statins, ezetimibe, and PCSK9 inhibitors.

Main Methods:

• Literature review of contemporary guidelines and clinical evidence.
• Analysis of lipid-lowering therapies including statins, ezetimibe, and PCSK9 inhibitors.
• Discussion of real-world challenges in secondary dyslipidemia prevention.

Main Results:

• Contemporary guidelines recommend specific lipid-lowering strategies for secondary prevention.
• Statins, ezetimibe, and PCSK9 inhibitors represent key therapeutic options with distinct evidence bases.
• Suboptimal lipid goal attainment and nonadherence are significant challenges in clinical practice.

Conclusions:

• Effective secondary prevention post-PCI requires comprehensive management of dyslipidemia.
• Understanding the evidence for various lipid-lowering agents is essential for optimizing patient care.
• Addressing adherence and goal attainment issues is critical for improving long-term cardiovascular outcomes.